Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.
October 1, 2024
Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S.
Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S.
Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.
Abbott (NYSE: ABT)+
today announced a major product launch, broadening the population that can utilize its continuous glucose monitoring (CGM) technology.
Embecta (Nasdaq:EMBC) today entered the insulin patch pump market with a major regulatory milestone.
The FDA clearance marks the first automated insulin delivery system for people with Type 2 diabetes.
Each patch now replaces up to 12 mealtime injections, equaling more than 1,000 fewer injections annually, according to a news release.
WASHINGTON, June 26, 2024 /PRNewswire/ — MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm is pleased to announce its role in aiding CamDiab’s artificial pancreas software, CamAPS FX, in achieving U.S. Food and Drug Administration (FDA) clearance.
Abbott (NYSE: ABT)+ today announced FDA clearance for two over-the-counter continuous glucose monitor (CGM) systems, Lingo and Libre Rio.
Abbott (NYSE: ABT)+ has secured a 510(k) clearance from the FDA for its over-the-counter Lingo glucose-monitoring biowearable.
CamDiab announced today that the FDA granted authorization for its CamAPS FX advanced adaptive closed-loop artificial pancreas app.